Literature DB >> 23043893

Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine.

Wiebke Hellenbrand1, Johannes Elias, Ole Wichmann, Manuel Dehnert, Matthias Frosch, Ulrich Vogel.   

Abstract

OBJECTIVES: To analyse serogroup (Sg)- and finetype-specific invasive meningococcal disease burden (IMD) in Germany, 2002-2010, with emphasis on effects of vaccination with conjugate SgC vaccines targeting one-year old children since 2006, including individual-based catch-up to 17 years of age.
METHODS: Serogroup- and age-specific IMD incidence and trends were calculated using statutory surveillance data. The national reference laboratory performed genetic finetyping. Vaccination uptake data were obtained from school entry surveys and prescription monitoring.
RESULTS: In persons <25 years, SgB and SgC IMD incidence decreased significantly from 0.63 to 0.32/100,000 and 0.26 to 0.10/100,000, respectively. The decline was significantly steeper for SgC than SgB in 1-5 year-olds, the primary vaccination target group, but not other ages. The slope of the SgC incidence curves was similar before and after vaccination implementation in all age groups; however, the decrease in incidence was steeper in states with higher vaccination uptake. Declining SgC incidence was associated with decreased SgC finetype diversity. An increase in SgY incidence was limited to adults.
CONCLUSIONS: Results suggest effects of the German SgC vaccination strategy are limited, although interpretation is complicated by already low and decreasing incidence before vaccination. More effective use of vaccination resources might be achieved by rigorously targeting adolescents in addition to 1-year-olds.
Copyright © 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23043893     DOI: 10.1016/j.jinf.2012.09.008

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  14 in total

1.  Reduction in Neisseria meningitidis infection in Italy after Meningococcal C conjugate vaccine introduction: A time trend analysis of 1994-2012 series.

Authors:  Chiara de Waure; Alessandro Miglietta; Darko Nedovic; Giovanna Mereu; Walter Ricciardi
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

Review 2.  Routinely vaccinating adolescents against meningococcus: targeting transmission & disease.

Authors:  Volker Vetter; Roger Baxter; Gülhan Denizer; Marco A P Sáfadi; Sven-Arne Silfverdal; Andrew Vyse; Ray Borrow
Journal:  Expert Rev Vaccines       Date:  2016-03-04       Impact factor: 5.217

3.  Risk of Invasive Meningococcal Disease in Men Who Have Sex with Men: Lessons Learned from an Outbreak in Germany, 2012-2013.

Authors:  Wiebke Hellenbrand; Heike Claus; Susanne Schink; Ulrich Marcus; Ole Wichmann; Ulrich Vogel
Journal:  PLoS One       Date:  2016-08-03       Impact factor: 3.240

4.  Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.

Authors:  Cecilia Buonsanti; Cristiana Balocchi; Carole Harfouche; Federica Corrente; Luisa Galli Stampino; Francesca Mancini; Marta Tontini; Padma Malyala; Simone Bufali; Barbara Baudner; Ennio De Gregorio; Nicholas M Valiante; Derek T O'Hagan; Rino Rappuoli; Ugo D'Oro
Journal:  Sci Rep       Date:  2016-07-21       Impact factor: 4.379

5.  Asymptomatic carriage of Neisseria meningitidis, Haemophilus influenzae, Streptococcus pneumoniae, Group A Streptococcus and Staphylococcus aureus among adults aged 65 years and older.

Authors:  Maria Drayß; Heike Claus; Kerstin Hubert; Katrin Thiel; Anja Berger; Andreas Sing; Mark van der Linden; Ulrich Vogel; Thiên-Trí Lâm
Journal:  PLoS One       Date:  2019-02-08       Impact factor: 3.240

6.  Epidemiology of two decades of invasive meningococcal disease in the Republic of Ireland: an analysis of national surveillance data on laboratory-confirmed cases from 1996 to 2016.

Authors:  D Bennett; P O'Lorcain; S Morgan; S Cotter; M Cafferkey; R Cunney
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

7.  Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011.

Authors:  Y A Li; R Tsang; S Desai; H Deehan
Journal:  Can Commun Dis Rep       Date:  2014-05-01

8.  Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.

Authors:  Markus Knuf; Olivier Romain; Klaus Kindler; Uta Walther; Phu-My Tran; Heidemarie Pankow-Culot; Thomas Fischbach; Dorothee Kieninger-Baum; Véronique Bianco; Yaela Baine; Jacqueline Miller
Journal:  Eur J Pediatr       Date:  2013-01-11       Impact factor: 3.183

9.  Implications of differential age distribution of disease-associated meningococcal lineages for vaccine development.

Authors:  Carina Brehony; Caroline L Trotter; Mary E Ramsay; Manosree Chandra; Keith A Jolley; Arie van der Ende; Françoise Carion; Lene Berthelsen; Steen Hoffmann; Hjördís Harðardóttir; Julio A Vazquez; Karen Murphy; Maija Toropainen; Manuela Caniça; Eugenia Ferreira; Mathew Diggle; Giles F Edwards; Muhamed-Kheir Taha; Paola Stefanelli; Paula Kriz; Steve J Gray; Andrew J Fox; Susanne Jacobsson; Heike Claus; Ulrich Vogel; Georgina Tzanakaki; Sigrid Heuberger; Dominique A Caugant; Matthias Frosch; Martin C J Maiden
Journal:  Clin Vaccine Immunol       Date:  2014-04-02

10.  Antibody Persistence in Young Children 5 Years after Vaccination with a Combined Haemophilus influenzae Type b-Neisseria meningitidis Serogroup C Conjugate Vaccine Coadministered with Diphtheria-Tetanus-Acellular Pertussis-Based and Pneumococcal Conjugate Vaccines.

Authors:  Juan Carlos Tejedor; Jerzy Brzostek; Ryszard Konior; Detlef Grunert; Devayani Kolhe; Yaela Baine; Marie Van Der Wielen
Journal:  Clin Vaccine Immunol       Date:  2016-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.